3 results
Approved WMOWill not start
Primary end points:Safety (>1 toxic death per arm) and tolerability (relevant grade 4 toxicities) in not more than 33% of patients for the three treatment arms.Secondary end points:* Reduction of grade 2-4 key side effects in the experimental…
Approved WMORecruiting
To study the effects of PF-06835919 on fructose tolerance and intrahepatic lipid content in patients with HFI.
Approved WMOCompleted
The purpose of this study is to compare STZ vs everolimus as first line treatment for advanced pNET and elucidate which sequence of STZ based chemotherapy and the mTOR inhibitor, everolimus, gives better results in terms of PFS in well…